Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
2.14
Change:
- 0.01
Volume:
1,157,500
4:00 PM ET on Jul 21, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

Jun 9, 2014
Dendreon Announces Leadership Transition

May 20, 2014
Treatment with PROVENGE® (sipuleucel-T) Induces Antigen Spread Associated with Overall Survival Benefits In Advanced Prostate Cancer

May 14, 2014
Dendreon Announces Presentation of PROVENGE® (sipuleucel-T) and DN24-02 Immuno-Oncology Data at the 2014 ASCO Annual Meeting



View all »Webcasts

May 8, 2014 at 9:00 AM ET
Q1 2014 Earnings Conference Call

Mar 4, 2014 at 11:20 AM ET
Cowen and Company 34th Annual Health Care Conference



View all »Presentations

MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Investor Relations
206-455-2220
ir@dendreon.com

Media
206-829-1622
media@dendreon.com